CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
P. Gougis,
M. Carton,
C. Tchokothe,
M. Campone,
F. Dalenc,
A. Mailliez,
C. Levy,
W. Jacot,
M. Debled,
M. Leheurteur,
T. Bachelot,
A. Hennequin,
C. Perrin,
A. Gonçalves,
L. Uwer,
J.C. Eymard,
T. Petit,
M.A. Mouret-Reynier,
E. Chamorey,
G. Simon,
M. Saghatchian,
C. Cailliot,
C. Le Tourneau
Affiliations
P. Gougis
Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; Department of Clinical Pharmacology, Centre D’Investigation Clinique Paris-Est, AP-HP, Pitié-Salpêtrière Hospital, PSL University, CLIP² Galilée, Paris, France
M. Carton
Department of Biostatistics, Institut Curie, Saint-Cloud, France
C. Tchokothe
Department of Biostatistics, Institut Curie, Saint-Cloud, France
M. Campone
Department of Medical Oncology, Institut de Cancérologie de L’Ouest, Nantes and Angers, France
F. Dalenc
Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
A. Mailliez
Department of Breast Cancer, Centre Oscar Lambret, Lille, France
C. Levy
Department of Medical Oncology, Centre François Baclesse, Caen, France
W. Jacot
Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier, France
M. Debled
Department of Medical Oncology, Institut Bergonié, Bordeaux, France
M. Leheurteur
Department of Medical Oncology, Henri Becquerel Centre, Rouen, France
T. Bachelot
Department of Biostatistics, Centre Léon Bérard, Lyon, France
A. Hennequin
Department of Medical Oncology, Center Georges François Leclerc, Dijon, France
C. Perrin
Department of Medical Oncology, Centre Eugène Marquis, Rennes, France
A. Gonçalves
Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
L. Uwer
Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
J.C. Eymard
Department of Medical Oncology, Centre Jean Godinot, Reims, France
T. Petit
Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France
M.A. Mouret-Reynier
Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France
E. Chamorey
Department of Biostatistics, Centre Antoine Lacassagne, Nice, France
G. Simon
Department of Research and Development, R&D Unicancer, Paris, France
M. Saghatchian
Department of Biostatistics, Institut Curie, Saint-Cloud, France
C. Cailliot
Department of Research and Development, R&D Unicancer, Paris, France
C. Le Tourneau
Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; U900 INSERM Research Unit, Saint-Cloud, France; Corresponding author. Department of Drug Development and Innovation (D3i), Institut Curie, 26, rue d’Ulm, 75005, Paris, France.
Purpose: The Time to First Metastatic Recurrence (TFMR) could be considered as an indirect reflection of the tumour growth kinetics which plays an important role in cancer. Molecular subtypes such as expression of estrogen receptor are known predictive factors of TFMR. The CinéBreast study aimed to identify predictive factors of the time to TFMR. Methods: The French Epidemiological Strategy and Medical Economics (ESME) Metastatic Breast Cancer (MBC) Database (NCT03275311) was used, which contains data from a cohort of metastatic breast cancer patients from 2008 to 2016 using retrospective data collection. It is a national multi-centre database. The impact of TFMR on overall survival (OS) since first metastasis was also evaluated. Results: Among 16 702 patients recorded in the ESME MBC database, 10 595 had an initially localised breast cancer with hormone receptor (HR) and HER2 status available, with a metastatic recurrence. Median follow up was 56 months. Median TFMR was 59 months (120: 24%). HER2+ and TNBC were respectively 4 times and 12 times (p < 0.0001) more likely to have a recurrence within 2 years when compared to the luminal subgroup. Short TFMR and HR-/HER2-subtype significantly correlated with a poor OS in multivariate analysis.Some patients with MBC (20% in HER2+, 10% in ER+/HER2-and <5% in the ER-/HER2-) were long-term survivors in all 3 subgroups. Conclusions: In this large-scale real-life data study, patients with a TNBC metastatic recurrence had a shorter TFMR. Short TFMR significantly correlated with worse overall survival.
